Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Novo Nordisk A/SNYSE: NVO

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of DKK 20.99B fell 20.8% year over year, behind the +4.8% change in trailing-twelve-month net income. Sequentially, it fell 56.8% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.

Context

  • Net income amounted to 33.1% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of DKK 102.38B (-0.1%) for the fiscal year ending Dec 2026, a slowdown from the +1.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 20.99B-56.8% QoQ
Last fiscal yearDec 2025
DKK 102.43B+1.4% YoY
LTMJun 2026
DKK 116.44B+4.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.8%+8.0%+28.8 pp
1 year+1.4%-0.1%-1.5 pp
3-year CAGR+22.6%+2.1%-20.6 pp
5-year CAGR+4.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

DKK · from the cash flow

Latest · FY2025
102.43B DKK
Year-over-year change
+1.4%
4-year CAGR
+21.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.8% is the 6th highest of 10, against a peer median of +15.4%.
  • Net income amounts to 35.3% of revenue for NVO, versus a peer median of 16.2%.
NVO Competitors
Net Income for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding NVO) —+15.4%+5.6%16.2%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.